Escala Medical is a Femtech medical device company from Israel that develops an incision free repair solution for women with pelvic organ prolapse (POP). Founded in 2014, the company’s goal is to let women restore pelvic floor function in minutes with an outpatient procedure, so they can quickly return to normal daily life. Escala is part of The Trendlines Group’s portfolio and focuses on shifting POP treatment from hospital surgery to safer, office based care.
Its main product, Mendit, is an FDA cleared device that repairs POP using a minimally invasive, vaginal, incision free approach. The device anchors sutures to pelvic ligaments through a navigation and fixation mechanism, so surgeons can suspend the vaginal apex without cutting tissue. This design reduces procedure time, anesthesia needs, and recovery time, while aiming to improve quality of life and access to care for women in the US and, soon, Europe and Asia.
Escala’s solution is designed to reduce surgical risk, pain, and hospital stays compared with conventional POP surgery. By moving treatment into the doctor’s office, it can reach more women, cut waiting times, and lower costs for health systems and patients.
Escala Medical has raised more than 8 million USD through grants and investments, including a €2.5 million EIC Accelerator grant and a $4.5 million round led by the EIC Fund. The new funding supports commercial rollout in the US, market entry in Europe, and expansion in Asia via regional partners.
Escala Medical develops incision free, minimally invasive devices to repair pelvic organ prolapse and improve women’s pelvic floor health.
Escala Medical is based in Misgav, Israel, as part of The Trendlines Group’s medical device incubator ecosystem.
Mendit is Escala’s FDA cleared POP repair device that anchors the vaginal apex to pelvic ligaments using an incision free vaginal approach.
The Mendit based procedure is designed to take about 10–20 minutes and is performed under mild local anesthesia in an outpatient setting.
The device is cleared and being commercialized in the US, with planned expansion into Europe after CE marking and into Southeast Asia through distribution partners.
Leave a Reply